Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst

Many companies will be glad to put 2020 behind them and you can certainly add Amarin (AMRN) to the list. Similarly, to other names, Covid-19 has played its part in the struggle, but the coronavirus has only exacerbated Amarin’s other non-macro related problems.Namely, the loss of a patent case and subsequent appeal for the company’s high triglyceride treatment Vascepa. Generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s won against Amarin and now plan on bringing their own generic...